GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Net Income

HBPCF (Helix BioPharma) Net Income : $-7.12 Mil (TTM As of Jan. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Helix BioPharma's Net Income for the three months ended in Jan. 2025 was $-0.96 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jan. 2025 was $-7.12 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Helix BioPharma's Earnings per Share (Diluted) for the three months ended in Jan. 2025 was $-0.10.


Helix BioPharma Net Income Historical Data

The historical data trend for Helix BioPharma's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Net Income Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.66 -6.42 -5.07 -4.76 -6.76

Helix BioPharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -1.34 -3.85 -0.97 -0.96

Helix BioPharma Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Helix BioPharma's Net Income for the fiscal year that ended in Jul. 2024 is calculated as

Net Income(A: Jul. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-6.755+0+0+0
=-6.76

Helix BioPharma's Net Income for the quarter that ended in Jan. 2025 is calculated as

Net Income(Q: Jan. 2025 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.956+0+0+0
=-0.96

Net Income for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Helix BioPharma  (OTCPK:HBPCF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Helix BioPharma's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jan. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Helix BioPharma Net Income Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.